• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在人类癌症中,C-RAF的突变很少见,因为与B-RAF相比,C-RAF的基础激酶活性较低。

Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.

作者信息

Emuss Victoria, Garnett Mathew, Mason Clive, Marais Richard

机构信息

The Institute of Cancer Research, Signal Transduction Team, Cancer Research UK Centre of Cell and Molecular Biology, London, United Kingdom.

出版信息

Cancer Res. 2005 Nov 1;65(21):9719-26. doi: 10.1158/0008-5472.CAN-05-1683.

DOI:10.1158/0008-5472.CAN-05-1683
PMID:16266992
Abstract

The protein kinase B-RAF is mutated in approximately 8% of human cancers. Here we show that presumptive mutants of the closely related kinase, C-RAF, were detected in only 4 of 545 (0.7%) cancer cell lines. The activity of two of the mutated proteins is not significantly different from that of wild-type C-RAF and these variants may represent rare human polymorphisms. The basal and B-RAF-stimulated kinase activities of a third variant are unaltered but its activation by RAS is significantly reduced, suggesting that it may act in a dominant-negative manner to modulate pathway signaling. The fourth variant has elevated basal kinase activity and is hypersensitive to activation by RAS but does not transform mammalian cells. Furthermore, when we introduce the equivalent of the most common cancer mutation in B-RAF (V600E) into C-RAF, it only has a weak effect on kinase activity and does not convert C-RAF into an oncogene. This lack of activation occurs because C-RAF lacks a constitutive charge within a motif in the kinase domain called the N-region. This fundamental difference in RAF isoform regulation explains why B-RAF is frequently mutated in cancer whereas C-RAF mutations are rare.

摘要

蛋白激酶B-RAF在约8%的人类癌症中发生突变。在此我们表明,在545个癌细胞系中,只有4个(0.7%)检测到密切相关的激酶C-RAF的推定突变体。其中两个突变蛋白的活性与野生型C-RAF的活性无显著差异,这些变体可能代表罕见的人类多态性。第三个变体的基础激酶活性和B-RAF刺激的激酶活性未改变,但其被RAS激活的能力显著降低,这表明它可能以显性负性方式作用来调节信号通路。第四个变体的基础激酶活性升高,对RAS激活高度敏感,但不能转化哺乳动物细胞。此外,当我们将B-RAF中最常见的癌症突变(V600E)引入C-RAF时,它对激酶活性只有微弱影响,且不会将C-RAF转化为癌基因。这种缺乏激活的情况是因为C-RAF在激酶结构域中一个称为N区的基序内缺乏组成性电荷。RAF同工型调节的这一根本差异解释了为什么B-RAF在癌症中频繁突变而C-RAF突变罕见。

相似文献

1
Mutations of C-RAF are rare in human cancer because C-RAF has a low basal kinase activity compared with B-RAF.在人类癌症中,C-RAF的突变很少见,因为与B-RAF相比,C-RAF的基础激酶活性较低。
Cancer Res. 2005 Nov 1;65(21):9719-26. doi: 10.1158/0008-5472.CAN-05-1683.
2
Functional analysis of mutations within the kinase activation segment of B-Raf in human colorectal tumors.人类结直肠癌中B-Raf激酶激活结构域内突变的功能分析。
Cancer Res. 2003 Dec 1;63(23):8132-7.
3
C-Raf inhibits MAPK activation and transformation by B-Raf(V600E).C-Raf 抑制 B-Raf(V600E)的 MAPK 激活和转化。
Mol Cell. 2009 Nov 13;36(3):477-86. doi: 10.1016/j.molcel.2009.10.017.
4
Two transforming C-RAF germ-line mutations identified in patients with therapy-related acute myeloid leukemia.在治疗相关急性髓系白血病患者中鉴定出两种转化型C-RAF种系突变。
Cancer Res. 2006 Apr 1;66(7):3401-8. doi: 10.1158/0008-5472.CAN-05-0115.
5
Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.野生型和突变型B-RAF通过涉及异源二聚化的不同机制激活C-RAF。
Mol Cell. 2005 Dec 22;20(6):963-9. doi: 10.1016/j.molcel.2005.10.022.
6
Oncogenic Ras, but not (V600E)B-RAF, protects from cholesterol depletion-induced apoptosis through the PI3K/AKT pathway in colorectal cancer cells.致癌性Ras而非(V600E)B-RAF通过PI3K/AKT途径保护结肠癌细胞免受胆固醇耗竭诱导的凋亡。
Carcinogenesis. 2009 Oct;30(10):1670-7. doi: 10.1093/carcin/bgp188. Epub 2009 Aug 20.
7
Regulation and role of Raf-1/B-Raf heterodimerization.Raf-1/B-Raf异二聚化的调控与作用
Mol Cell Biol. 2006 Mar;26(6):2262-72. doi: 10.1128/MCB.26.6.2262-2272.2006.
8
Different effects of point mutations within the B-Raf glycine-rich loop in colorectal tumors on mitogen-activated protein/extracellular signal-regulated kinase kinase/extracellular signal-regulated kinase and nuclear factor kappaB pathway and cellular transformation.结直肠癌中B-Raf富含甘氨酸环内点突变对丝裂原活化蛋白/细胞外信号调节激酶激酶/细胞外信号调节激酶及核因子κB信号通路和细胞转化的不同影响
Cancer Res. 2004 May 15;64(10):3428-35. doi: 10.1158/0008-5472.CAN-03-3591.
9
Functional analysis of the regulatory requirements of B-Raf and the B-Raf(V600E) oncoprotein.B-Raf及B-Raf(V600E)癌蛋白调控需求的功能分析
Oncogene. 2006 Oct 12;25(47):6262-76. doi: 10.1038/sj.onc.1209640. Epub 2006 May 15.
10
Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia.结直肠肿瘤中与BRAF和KRAS突变相关的表型模式的相似性。
Cancer Res. 2002 Nov 15;62(22):6451-5.

引用本文的文献

1
Value of a BRAF and lymphocyte subset-based nomogram for discriminating benign lesions from papillary thyroid carcinoma in C-TIRADS 3 and higher nodules.基于BRAF和淋巴细胞亚群的列线图在鉴别C-TIRADS 3类及以上结节中的甲状腺乳头状癌与良性病变方面的价值。
Front Endocrinol (Lausanne). 2025 Aug 15;16:1608222. doi: 10.3389/fendo.2025.1608222. eCollection 2025.
2
Cryo-EM structures of CRAF/MEK1/14-3-3 complexes in autoinhibited and open-monomer states reveal features of RAF regulation.处于自抑制和开放单体状态的CRAF/MEK1/14-3-3复合物的冷冻电镜结构揭示了RAF调节的特征。
Nat Commun. 2025 Sep 1;16(1):8150. doi: 10.1038/s41467-025-63227-2.
3
MEK Inhibition in Glioblastoma: Current Perspectives and Future Directions.
胶质母细胞瘤中的MEK抑制:当前观点与未来方向
Int J Mol Sci. 2025 Jul 17;26(14):6875. doi: 10.3390/ijms26146875.
4
Small Molecule B-RAF Inhibitors as Anti-Cancer Therapeutics: Advances in Discovery, Development, and Mechanistic Insights.小分子B-RAF抑制剂作为抗癌治疗药物:发现、开发及机制研究进展
Int J Mol Sci. 2025 Mar 16;26(6):2676. doi: 10.3390/ijms26062676.
5
From bench to bedside: murine models of inherited and sporadic brain arteriovenous malformations.从 bench 到床边:遗传性和散发性脑动静脉畸形的小鼠模型
Angiogenesis. 2025 Feb 3;28(2):15. doi: 10.1007/s10456-024-09953-5.
6
Reversible control of kinase signaling through chemical-induced dephosphorylation.通过化学诱导去磷酸化实现激酶信号的可逆控制。
Commun Biol. 2024 Aug 31;7(1):1073. doi: 10.1038/s42003-024-06771-9.
7
Regulation of RAF family kinases: new insights from recent structural and biochemical studies.RAF 家族激酶的调控:来自近期结构和生化研究的新见解。
Biochem Soc Trans. 2024 Jun 26;52(3):1061-1069. doi: 10.1042/BST20230552.
8
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework.用于癌症治疗的ERK通路激动作用:证据、见解及一个靶点发现框架
NPJ Precis Oncol. 2024 Mar 14;8(1):70. doi: 10.1038/s41698-024-00554-5.
9
The role of CRAF in cancer progression: from molecular mechanisms to precision therapies.CRAF 在癌症进展中的作用:从分子机制到精准治疗。
Nat Rev Cancer. 2024 Feb;24(2):105-122. doi: 10.1038/s41568-023-00650-x. Epub 2024 Jan 9.
10
Unveiling the domain-specific and RAS isoform-specific details of BRAF kinase regulation.揭示 BRAF 激酶调节的域特异性和 RAS 异构体特异性细节。
Elife. 2023 Dec 27;12:RP88836. doi: 10.7554/eLife.88836.